Roche shares data from phase 3 trial of Xolair as allergy treatment

Betsy Goodfellow | February 26, 2024 | News story | Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy 

Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed the safety and efficacy of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods.

The results were published in the New England Journal of Medicine (NEJM) and featured in a symposium at the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.

The trial demonstrated that treatment with Xolair increased the amount of allergen that it took to cause moderate to severe allergic reactions in multi-food allergic people as young as one-year. The allergens included peanuts, milk, egg, wheat and tree nuts (cashew, hazelnut and walnut).

Robert Wood MD, director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, US, and principal investigator on the study, commented: “Over the past 35 years, I have seen how debilitating food allergies can be for patients and their loved ones, as they are consumed by the fear of accidental exposure. While allergic reactions to exposures are common and often severe, there have been limited treatment advancements for food allergy. The results of the OUtMATCH study showed that anti-IgE therapy could significantly reduce the occurrence of allergic reactions across multiple foods in the event of an accidental exposure.”

Betsy Goodfellow

Related Content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

Latest content